Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MedAlliance

Request full access

Developing ground-breaking technology for the treatment of coronary and peripheral artery disease

Nyon, SwitzerlandFounded 2008Health Tech & Medtech

About MedAlliance

Established in 2008 by Jeffrey B. Jump, MedAlliance SA is a Swiss-based medical technology company focused on developing and commercializing drug-device combination products for treating coronary and peripheral artery disease. Mr. Jump, who serves as Chairman and CEO, leveraged his extensive experience in the medical device industry, including a 13-year tenure as CEO of Biosensors International, to identify shortcomings in existing stent technologies. This insight led to the company's mission: to create a treatment that delivers a therapeutic drug without leaving a permanent metal implant behind.

The company's core product is the SELUTION SLR™ (Sustained Limus Release), a drug-eluting balloon (DEB). This device addresses atherosclerosis, the hardening of arteries, by delivering the anti-restenotic drug sirolimus to the affected vessel during an angioplasty procedure. Its technology features unique MicroReservoirs—a blend of biodegradable polymer and sirolimus—that coat the balloon. When the balloon is inflated within the artery, the proprietary Cell Adherent Technology (CAT™) ensures the MicroReservoirs adhere to the vessel wall, providing a controlled and sustained drug release for up to 90 days. This approach is designed to prevent restenosis, or the re-narrowing of the artery, a common complication with permanent metal stents.

MedAlliance primarily serves interventional cardiologists and vascular surgeons in hospitals and clinics worldwide. The company achieved significant regulatory milestones, including CE Mark approvals in 2020 for both peripheral and coronary artery disease treatment. It also became the first DEB company to receive multiple 'Breakthrough Device Designations' and Investigational Device Exemption (IDE) approvals from the U.S. FDA for various indications, including in-stent restenosis and below-the-knee lesions. In October 2023, the company's trajectory culminated in a landmark acquisition by Cordis, a global leader in interventional vascular technology. The deal, valued at up to $1.135 billion, involved an upfront payment and future milestone-based payments, reflecting the significant market potential of the SELUTION SLR™ technology. The acquisition provides MedAlliance with Cordis's extensive global sales and distribution network, aiming to accelerate the worldwide adoption of its stent-less angioplasty solution.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
61
Open positions
None listed
Dealroom signal
61.5/100
Industry
Health
Sub-industry
Medical Devices
Sector
Cardiology and cardiovascular, Tech for Hospitals and Clinics, DT and LS, science-based
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Feb 2022
Capital deployed
—
Preferred round
ACQUISITION

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Oct 2022 $200M $325M Cordis ↗
GROWTH EQUITY VCOther financing Mar 2021 $50M — CITIC Capital —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

MedAlliance website traffic

Latest recorded traffic for MedAlliance is 200 monthly website visits, down 33.3% over the last three months. MedAlliance's team declined 22.8% over the past year.

Latest monthly visits200 3-month web change-33.3% 1-year team growth-22.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
inHEARTAI-enabled digital twin of the heart Pessac, France Operational 48 $15M $44M
Volta MedicalA med-tech company based in Marseille that develops artificial intelligence (AI) intended for interventional cardiology Marseille, France Operational
Filterlex MedicalFilterlex created the CAPTIS® intra-aortic EPD to deflect, capture, and remove embolic particles during TAVI. This new EPD offers full-body protection by trapping and eliminating embolic debris Yokneam Ilit, Israel Operational
EmbolineDeveloped the only embolic protection device designed to provide complete protection of the brain and other critical organs by capturing and removing emboli produced during the procedure Santa Cruz, United States Operational
CathworksMedical technology company focused transforming how cardiovascular disease is diagnosed and treated Kfar Saba, Israel Acquired
MirusFocused on the design of innovative solutions for the treatment of spinal and orthopaedic degeneration and deformities Marietta, United States Operational
Hi-D ImagingHigh resolution, high dimension data imaging software to help physicians with cardiovascular pre-operational planning Winterthur, Switzerland Operational
NewMed MedicalDeveloping, manufacturing and marketing advanced interventional artificial heart valve systems Pudong, China Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

MedAlliance in the Nyon ecosystem

Live from Dealroom

The MedAlliance office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • CITIC Capital

Other known investors1 additional known investor

  • Cordis
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇺🇸 United States72.7%
🇨🇭 Switzerland12.1%
🇬🇧 United Kingdom3%
🇩🇪 Germany3%
🇮🇹 Italy3%
Top 5 of 7 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MedAlliance on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MedAlliance’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.